The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
In the U.K., Preventx, a leading remote testing provider, reportedly processes over 300,000 sexual health tests per month, 14 demonstrating the throughput potential of this model. Other major test manufacturers include BD (Becton, Dickinson and Company), BioSure UK, myLAB Box and LetsGetChecked. Overall, hybrid testing services bridge consumer convenience with clinical-grade accuracy, typically returning results within a few days. 15
increase from around 5% in 2015 to 43% by 2022. 12 In the United States, self-sampling options are now available in 48 of 50 states (all but New York and Rhode Island), with free testing programs offered in 22 states and Washington, D.C. 13 While challenges remain around sample stability, logistics and turnaround times, innovations that improve ease of use, shipping and scalability are expanding adoption of this testing model.
Complementary Modalities for Comprehensive Coverage
Rather than competing, laboratory-based, point-of-care, at-home and self-collection tests increasingly complement one another, creating a comprehensive diagnostic ecosystem. This is particularly valuable in remote or underserved regions and communities where stigma around STIs limits access to testing: • Centralized laboratories provide the depth and reliability required for confirmatory testing and population-level surveillance • Point-of-care (POC) platforms offer immediacy in clinical settings, enabling rapid intervention and outbreak control • At-home and hybrid models extend access and engagement, reaching populations historically underserved by traditional healthcare systems For assay developers, the expanding range of diagnostic formats offers new avenues for innovation. The future lies in integration rather
than replacement, with laboratories supporting complex panels, point-of-care systems addressing urgent or decentralized testing and at-home kits extending access to new populations. Differenti- ation will depend on user-friendly design, digital integration and supply-chain simplicity, enabling tests that are easy to use, ship and store while expanding reach and scalability. At the same time, molecular innovation is increasingly bridging these diagnostic modali- ties. Advances such as isothermal amplification, CRISPR-based detection and emerging multiplex platforms are helping to combine laboratory-grade performance with near-patient accessibility. These innovations are enabling assays that can detect multiple STI targets from a single sample and better reflect real-world patterns of co-infection and clinical presentation. This shift is explored further in Meridian’s article, “Smarter STI Diagnostics: Multiplexing, Reagent Innovation and Digital Connectivity .”
GENengnews.com | 17
Powered by FlippingBook